Abbott Laboratories stock has declined 22% following disappointing quarterly results with weak diagnostic and nutrition segments. However, the article argues it presents a buying opportunity due to strong medical device performance (up 12.3%), promising growth prospects in continuous glucose monitoring and structural heart products, a $21 billion...

Abbott Laboratories is presented as a superior alternative to volatile cannabis stocks like Tilray, offering 54 consecutive years of dividend increases and expected 10% EPS growth in 2026. The company benefits from its pending $23 billion acquisition of Exact Sciences and new FDA-approved heart rhythm treatment, though it faces headwinds from Fre...

MDxHealth SA (NASDAQ: MDXH), a precision diagnostics company, announced it will release its fourth quarter and full year 2025 financial results on February 26, 2026, followed by a conference call. The company also reported preliminary 2025 revenues, issued 2026 guidance, and amended earnout terms with Exact Sciences. Additionally, MDxHealth is co...

Abbott Laboratories' stock fell nearly 10% after missing Q4 revenue expectations due to higher manufacturing costs in its nutrition segment. However, the analyst argues the sell-off was overdone, citing Abbott's strong EPS growth, accelerating 2026 revenue guidance (6.5-7.5% organic growth), diversified portfolio, and pending acquisition of Exact...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, missing consensus expectations of $11.80 billion. The company issued disappointing guidance for Q1 2026 and fiscal 2026, projecting adjusted earnings below Wall Street estimates. The stock fell 7.37% to a new 52-week low following the announcement.